Caris Life Sciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
CAI$25.57+1.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
CARIS LIFE SCIENCES, INC
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
| (amounts in thousands, except share data) | As of September 30, | As of December 31, |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash, cash equivalents, and restricted cash | $754,739 | $65,442 |
| Short-term marketable securities | 2,272 | 2,201 |
| Accounts receivable | 26,697 | 88,244 |
| Supplies | 49,303 | 39,572 |
| Prepaid expenses and other current assets | 21,234 | 20,270 |
| Total current assets | 854,245 | 215,729 |
| Property and equipment, net | 63,997 | 67,817 |
| Goodwill | 19,344 | 19,344 |
| Other assets | 46,985 | 40,844 |
| Total assets | $984,571 | $343,734 |
| Liabilities, Redeemable Convertible Preferred Stock, and Shareholders' Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $28,999 | $27,791 |
| Accrued expenses and other current liabilities | 56,867 | 77,542 |
| Current portion of indebtedness | 164 | 60,090 |
| Total current liabilities | 86,030 | 165,423 |
| Long-term indebtedness, net of debt discounts | 376,296 | 319,438 |
| Warrant liabilities | — | 91,642 |
| Other long-term liabilities | 43,881 | 44,418 |
| Total liabilities | 506,207 | 620,921 |
| Commitments and contingencies (see note 9) | ||
| Redeemable convertible preferred stock: | ||
| Series A preferred stock, par value $0.001: no and 490,000,000 shares authorized as of September 30, 2025 and December 31, 2024; no and 485,795,293 shares issued and outstanding as of September 30, 2025 and December 31, 2024; and $296,335 aggregate liquidation preference as of December 31, 2024 | — | 709,261 |
| Series B preferred stock, par value $0.001: no and 30,000,000 shares authorized as of September 30, 2025 and December 31, 2024; no and 29,629,630 shares issued and outstanding as of September 30, 2025 and December 31, 2024; and $16,000 aggregate liquidation preference as of December 31, 2024 | — | 42,963 |
| Series C preferred stock, par value $0.001: no and 142,000,000 shares authorized as of September 30, 2025 and December 31, 2024; no and 116,200,835 shares issued and outstanding as of September 30, 2025 and December 31, 2024; and $408,715 aggregate liquidation preference as of December 31, 2024 | — | 408,715 |
| Series D preferred stock, par value $0.001: no and 102,600,000 shares authorized as of September 30, 2025 and December 31, 2024; no and 102,516,283 shares issued and outstanding as of September 30, 2025 and December 31, 2024; and $1,060,712 aggregate liquidation preference as of December 31, 2024 | — | 1,060,712 |
| Redeemable convertible preferred stock | — | 2,221,651 |
| Shareholders' equity (deficit): | ||
| Preferred stock, $0.001 par value per share; 100,000,000 and no shares authorized as of September 30, 2025 and December 31, 2024, respectively; no shares issued and outstanding as of September 30, 2025 and December 31, 2024 | — | — |
| Common stock $0.001 par value; 2,800,000,000 and 1,150,000,000 shares authorized as of September 30, 2025 and December 31, 2024, respectively; 283,723,897 and 36,686,819 shares issued as of September 30, 2025 and December 31, 2024, respectively; 282,103,259 and 36,504,319 shares outstanding as of September 30, 2025 and December 31, 2024, respectively; shares issued and outstanding include 23,446 and 662,000 unvested shares subject to repurchase as of September 30, 2025 and December 31, 2024, respectively | 283 | 38 |
| Treasury stock at cost, 1,620,638 and 182,500 shares of common stock as of September 30, 2025 and December 31, 2024, respectively | (16,917) | (330) |
| Additional paid-in capital | 3,124,943 | — |
| Related party promissory note receivable (see note 7) | — | (26,456) |
| Accumulated deficit | (2,630,693) | (2,472,300) |
| Accumulated other comprehensive income | 748 | 210 |
| Total shareholders' equity (deficit) | 478,364 | (2,498,838) |
| Total liabilities, redeemable convertible preferred stock, and shareholders' equity (deficit) | $984,571 | $343,734 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.